Table 1.
Baseline Participant Characteristics by Study Arm
| All (80) | DHEA + COC Arm (43) |
Placebo Arm (37) | P * | ||
|---|---|---|---|---|---|
| Mean ± SD | |||||
| Age, yr | 18.1 ± 2.7 | 18.0 ± 2.5 | 18.3 ± 2.8 | 0.84 | |
| Height, cm | 164.0 ± 7.0 | 164.4 ± 6.7 | 163.6 ± 7.5 | 0.47 | |
| Weight, kg | 48.6 ± 5.8 | 49.1 ± 5.9 | 48.0 ± 5.6 | 0.55 | |
| BMI, kg/m2 | 18.0 ± 1.5 | 18.1 ± 1.5 | 17.8 ± 1.5 | 0.24 | |
| Fat mass, kg | 8.6 ± 2.7 | 8.8 ± 2.8 | 8.4 ± 2.6 | 0.55 | |
| Lean mass, kg | 37.4 ± 4.5 | 37.5 ± 4.2 | 37.2 ± 4.8 | 0.68 | |
| 25(OH)D, ng/mL | 38.3 ± 14.4 | 39.8 ± 13.4 | 36.7 ± 15.6 | 0.14 | |
| PTH, pg/mL | 29.7 ± 11.2 | 30.1 ± 11.4 | 29.4 ± 11.1 | 0.71 | |
|
| |||||
| Median (Q1–Q3) | |||||
| Duration of AN, mo | 12 (4–28) | 12 (6–40) | 9 (4–18) | 0.07 | |
| Months amenorrhea † | 11 (5–20) | 9 (6–18) | 12 (5–20) | 0.63 | |
|
| |||||
| N (%) | |||||
| White | 71 (89) | 39 (91) | 32 (86) | 0.73 | |
| Hispanic | 2 (3) | 1 (2) | 1 (3) | 1.0 | |
|
| |||||
| Lumbar spine: ‡ | ≤ –1 SD | 41 (51) | 20 (47) | 21 (57) | 0.38 |
| ≤ –2 SD | 13 (16) | 8 (19) | 5 (14) | 0.76 | |
|
| |||||
| Total hip: | ≤ –1 SD | 19 (24) | 9 (21) | 10 (29) | 0.60 |
| ≤ –2 SD | 3 (4) | 1 (2) | 2 (6) | 0.58 | |
|
| |||||
| Whole body: | ≤ –1 SD | 11 (14) | 4 (9) | 7 (19) | 0.33 |
| ≤ –2 SD | 1 (1) | 0 (0) | 1 (3) | 0.46 | |
*
Independent-sample t-test, corroborated by non-parametric test, or Fisher Exact test comparing distribution in DHEA+COC and placebo arms.
†
Excludes five participants with primary amenorrhea; includes six participants who were on COCs at time of recruitment and discontinued use of the medication for at least 1 month before the baseline visit.
‡
aBMD Z-score.